Adaptimmune Therapeutics PLC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Adaptimmune Therapeutics plc announced its voluntary delisting from The Nasdaq Capital Market and subsequent deregistration to reduce costs and maximize value from remaining assets.
Adaptimmune Therapeutics plc received a Nasdaq notice for failing to meet the minimum bid price requirement, with a deadline of December 1, 2025, to regain compliance.
Adaptimmune Therapeutics plc received a Nasdaq notice for failing to meet the minimum Market Value of Listed Securities requirement, initiating a 180-day compliance period.
Adaptimmune Therapeutics plc announced the appointment of Christopher Hill as its new Chief Financial Officer, effective September 10, 2025, under a consulting agreement.
Adaptimmune Therapeutics plc disclosed the termination of its Chief Financial Officer, Gavin Wood, and Chief Patient Supply Officer, John Lunger, due to redundancy, detailing their severance packages.
Adaptimmune Therapeutics PLC announced the departure of its Chief Commercial Officer, Cintia Piccina, due to redundancy, with a severance package of $473,800.
Adaptimmune Therapeutics PLC faces potential delisting from Nasdaq due to its stock price falling below $0.10 for ten consecutive trading days, prompting a planned hearing request.
Adaptimmune Therapeutics announced Q2 2025 financial results, a strategic sale of its commercial and late-stage assets to US WorldMeds for $55 million upfront, and a subsequent debt repayment and restructuring.
Adaptimmune Therapeutics PLC announced the termination of its Chief Medical Officer, Chief Scientific Officer, and Chief Financial Officer due to redundancy, detailing their severance packages.
Adaptimmune Therapeutics PLC completed the sale of its TECELRA, lete-cel, afami-cel, and uza-cel cell therapy assets for an initial $55 million cash, simultaneously terminating a $29.1 million loan agreement with Hercules Capital, Inc.
Adaptimmune Therapeutics plc has entered into a definitive agreement to sell its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55 million cash upfront and up to $30 million in future milestone payments, alongside a significant corporate restructuring.
Adaptimmune Therapeutics PLC has reached a settlement agreement with The University of Texas M.D. Anderson Cancer Center, resolving a breach of contract lawsuit and avoiding further litigation costs.
Adaptimmune Therapeutics PLC announced that all 13 proposals, including the re-election of directors, auditor appointments, and new share option schemes, were approved by shareholders at its Annual General Meeting held on May 29, 2025.
Adaptimmune announced its Q1 2025 financial results, highlighting the Tecelra launch progress and providing full-year sales guidance of $35-$45 million.
Adaptimmune Therapeutics received approval to transfer its listing to the Nasdaq Capital Market, gaining additional time to meet the minimum bid price requirement.
Adaptimmune Therapeutics has amended its severance agreement with CFO Gavin Wood, extending his employment until August 31, 2025, due to redundancy.
Adaptimmune Therapeutics plc amended its loan agreement with Hercules Capital, prepaying $25 million of the loan amount and adjusting reporting provisions.
Adaptimmune reports Q4 and full year 2024 business update, highlighting Tecelra launch progress and strategic options evaluation.
Adaptimmune Therapeutics announces the departure of its Chief Business & Strategy Officer and Chief Financial Officer as part of a broader restructuring effort.
Adaptimmune is restructuring to focus on its sarcoma franchise, projecting $400 million in peak sales, while also reporting positive clinical trial results for lete-cel and progress in the Tecelra launch.
Adaptimmune's lete-cel demonstrated a 42% clinical response rate in patients with advanced synovial sarcoma or MRCLS, meeting the primary endpoint of its pivotal Phase 2 trial.
Adaptimmune Therapeutics has been notified by Nasdaq that it is not in compliance with listing rules due to its share price falling below $1.00 for 30 consecutive days.
Adaptimmune Therapeutics has reached a mutual release and resolution agreement with Genentech, resulting in a $12.5 million payment to Adaptimmune and the termination of their collaboration agreement.
Adaptimmune announced FDA approval for Tecelra, the first engineered cell therapy for a solid tumor, and reported a significant increase in revenue for Q2 2024.
Adaptimmune Therapeutics has received FDA approval for TECELRA, the first engineered cell therapy for a solid tumor cancer, specifically for advanced synovial sarcoma.
Adaptimmune Therapeutics has amended and restated its executive severance policy, increasing benefits for executives upon termination without cause or resignation for good reason, especially following a change in control.
Adaptimmune Therapeutics has amended its executive severance policy, increasing benefits for executives upon termination without cause or resignation for good reason, especially following a change in control.
Adaptimmune and Galapagos have entered a clinical collaboration and licensing agreement for Adaptimmune's uza-cel T-cell therapy, targeting head & neck cancer, with potential for expansion into other solid tumors.
Adaptimmune announced its Q1 2024 financial results and provided a business update, highlighting progress towards the potential commercial launch of afami-cel and a new debt financing agreement.
Adaptimmune has secured a $125 million term loan facility with Hercules Capital to bolster its balance sheet as it prepares for the commercial launch of afami-cel and the development of lete-cel.